➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
McKesson
Merck
Boehringer Ingelheim
Moodys

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 9,029,081

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,029,081
Title:Characterization of N-glycans using exoglycosidases
Abstract: The present disclosure provides methods for analyzing structure and/or composition of N-glycans. Such methods often involve digestion of N-glycans with multiple exoglycosidases. In some embodiments, N-glycans are digested with multiple exoglycosidases simultaneously. In some embodiments, N-glycans are digested with multiple exoglycosidases sequentially. In some embodiments, methods in accordance with the present disclosure involve comparison of cleavage products of N-glycans that have been digested with multiple exoglycosidases simultaneously to N-glycans that have been digested with multiple exoglycosidases sequentially.
Inventor(s): Parsons; Ian Christopher (Belmont, MA), Bulik; Dorota A. (Winchester, MA), Bosques; Carlos J. (Arlington, MA), Thiruneelakantapillai; Lakshmanan (Boston, MA), Collins; Brian Edward (Arlington, MA)
Assignee: Momenta Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:13/720,192
Patent Claims:see list of patent claims

Details for Patent 9,029,081

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Momenta Pharmaceuticals, Inc. (Cambridge, MA) 2027-04-16 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Momenta Pharmaceuticals, Inc. (Cambridge, MA) 2027-04-16 RX search
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Start Trial Momenta Pharmaceuticals, Inc. (Cambridge, MA) 2027-04-16 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Momenta Pharmaceuticals, Inc. (Cambridge, MA) 2027-04-16 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02   Start Trial Momenta Pharmaceuticals, Inc. (Cambridge, MA) 2027-04-16 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Momenta Pharmaceuticals, Inc. (Cambridge, MA) 2027-04-16 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 002 2001-05-07   Start Trial Momenta Pharmaceuticals, Inc. (Cambridge, MA) 2027-04-16 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Boehringer Ingelheim
Express Scripts
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.